Krystal Biotech to Present Update on KB103 Program for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
47
Krystal Biotech to Present Update on KB103 Program for Treatment of Dystrophic Epidermolysis Bullosa at debra Care Conference 2018

PITTSBURGH, July 16, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS ), a gene therapy company developing topical and intradermal “off-the-shelf” treatments for rare dermatological diseases, today announces a presentation on the Company’s lead product candidate, KB103, the first-ever topically-applied gene therapy being developed for the treatment of dystrophic epidermolysis bullosa (DEB). The presentation will be delivered by Suma Krishnan, founder and chief operating officer of Krystal, at the biennial debra Care Conference, to be held in Chandler, Ariz., July 22-25, 2018.

The details of the presentation are as follows:

Date: Tuesday, July 24
Time: 9:45 a.m. – 10:30 a.m. MDT
Title: KB103:  A Topical Off the Shelf Gene Therapy
Presenter: Suma Krishnan Founder and Chief Operating Officer Krystal Biotech
Location: Sheraton Grand at Wild Horse Pass, Chandler, Ariz.

About 2018 debra Care Conference The debra Care Conference (formerly known as the Patient Care Conference) is a national conference specifically designed for the epidermolysis bullosa (EB) community and is held every two years in different cities across the U.S. debra of America invites those with EB as well as their families, advocates, and care providers to listen to, meet with, and learn from leading medical professionals as well as academic researchers and organizations who are conducting research into treatments and a cure for EB. Bandage manufacturers and distributors also attend and demonstrate their products and services. Most importantly, the conference allows those impacted by EB to meet new families and reconnect with others from around the country.

About KB103 KB103 is Krystal’s lead product candidate that seeks to use gene therapy to treat dystrophic epidermolysis bullosa, or DEB, an incurable skin blistering condition caused by a lack of collagen in the skin. KB103 is a replication-defective, non-integrating viral vector that has been engineered employing Krystal’s STAR-D platform to deliver functional human COL7A1 genes directly to the patients’ dividing and non-dividing skin cells. HSV-1 is Krystal’s replication-deficient, non-integrating viral vector that can penetrate skin cells more efficiently than other viral vectors. Its high payload capacity allows it to accommodate large or multiple genes and its low immunogenicity makes it a suitable choice for direct and repeat delivery to the skin.

About the STAR-D Gene Therapy Platform   Krystal’s Skin TARgeted Delivery platform, or STAR-D platform, is a proprietary gene therapy platform consisting of an engineered viral vector and skin-optimized gene transfer technology that Krystal is employing to develop off-the-shelf treatments for dermatological diseases for which there are no known effective treatments. The company believes that the STAR-D platform provides an optimal approach for treating dermatological conditions due to the nature of the HSV-1 viral vector it has created. Certain inherent features of the HSV-1 virus, combined with the ability to strategically modify the virus in the form employed as a gene delivery backbone, provide the STAR-D platform with several advantages over other viral vector platforms for use in dermatological applications.

About Dystrophic Epidermolysis Bullosa, or DEB Dystrophic epidermolysis bullosa, or DEB, is an incurable, often fatal skin blistering condition caused by a lack of collagen protein in the skin. It is caused by mutations in the gene coding for type VII collagen, or COL7, a major component of anchoring fibrils, which connect the epidermis to the underlying dermis, and provide structural adhesion between these skin layers in a normal individual. The lack of COL7 in DEB patients causes blisters to occur in the dermis as a result of separation from the epidermis.  This makes the skin incredibly fragile, leading to blistering or skin loss at the slightest friction or knock. It is progressive and incredibly painful.

The most severe form of DEB is recessive DEB, or RDEB, which is caused by null mutations in the COL7A1 gene.  DEB also occurs in the form of dominant DEB, or DDEB, which is considered to be a milder form of DEB.  There are no known treatments affecting the outcome of either form of the disease, and the current standard of care for DEB patients is limited to palliative treatments.  Krystal is developing KB103 for the treatment of the broad DEB population, including both recessive and dominant forms of the disease.

About Krystal Biotech Krystal Biotech, Inc. (NASDAQ: KRYS ) is a gene therapy company dedicated to developing and commercializing topical and intradermal “off-the-shelf” novel treatments for patients suffering from rare dermatological diseases. For more information, please visit  http://www.krystalbio.com . 

Forward-Looking Statements This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding the potential of KB103 to treat the underlying causes of DEB, the timetable for bringing GMP manufacturing in-house and the potential for rapid development of the company’s clinical programs.  You can identify forward-looking statements because they contain words such as “believes” and “expects.” Forward-looking statements are based on Krystal’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in Krystal’s filings with the Securities and Exchange Commission, including its registration statement on Form S-1 and Form 10-K, as amended from time to time, under the caption “Risk Factors.”

CONTACTS:

Investors: Ashley R. Robinson  LifeSci Advisors arr@lifesciadvisors.com  

Media : Darren Opland, PhD LifeSci Public Relations darren@lifescipublicrelations.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Alliance for Women in Media Champions Change in 2026

Updated Category News Views 87

A Celebration of Trailblazing Women in Media If there's one thing I've learned about strong leadership, it's that you can't fake authenticity. Today, we're tipping our hats to some genuine trailblazers. The Alliance for Women in Media (AWM) held its annual Gracies Leadership Awards, celebrating the achievements and vision of seven remarkable women. Honoring the...

Continue Reading
Paris Baguette Expands U.S. Presence with New Georgia Café

Updated Category News Views 141

Café Culture Meets Expansion Chase You ever sip a cup of coffee and hear the rustle of opportunity in the steam? That's what's brewing at Paris Baguette with their new opening in Peachtree Corners, Georgia. This isn't just another café setting up shop; it's part of a larger scheme—expanding their sweet slice of the global market pie. Paris Baguette's Georgia Gamble...

Continue Reading
Vipshop Prepares for Q3 Financial Results Release

Updated Category News Views 93

Countdown to Vipshop's Third Quarter Results November 24th might just be another day on the calendar for some, but for those of us keeping tabs on the markets, it's a make-or-break moment for Vipshop Holdings Limited. The off-price retail titan from China, trailing under the ticker NYSE:VIPS, is gearing up to swing the doors wide open on its third-quarter financial...

Continue Reading
Mars Moves on Cash Tender Offers for Seniors' Notes

Updated Category News Views 104

A Strategic Financial Maneuver or a Casual Gambit? Okay, what’s Mars up to now, you ask? Here we go with this. The behemoth behind some of your favorite snacks and pet indulgences is making waves—not with candy, but with cash. Mars, Incorporated is rolling out tender offers to buy back a substantial chunk of its Senior Notes for $2 billion in cold, hard cash. When a...

Continue Reading
Gold Tumbles: Kinross Faces Class Action Lawsuit

Updated Category News Views 120

Digging Deep into Kinross's Legal Fallout Well, here's a doozy for those investing in the precious metal market. Kinross Gold Corporation (NYSE: KGC) finds itself knee-deep in legal muck. Investors who bought into the Canadian gold miner's promises might be scrambling, as a class action lawsuit has just been lobbed their way. The culprit? A hefty drop-off in their...

Continue Reading
Ozelle Unveils AI-Powered Hematology Tool at MEDICA 2026

Updated Category News Views 124

Pioneering a New Era in Hematology In the fast-paced world of blood analysis, standing still means being left in the dust. Ozelle, with its AI-powered innovative tool, is making waves at MEDICA 2026 in Düsseldorf. Meet O-Cyte 1, an automated hematology analyzer that's merging high-resolution cell imaging with routine CBC (Complete Blood Count) testing. Sounds like...

Continue Reading
Older Adults Embrace Cosmetic Dentistry for Confidence

Updated Category News Views 61

Why the Shift to Cosmetic Dentistry Later in Life? Aging doesn't just wrinkle your skin; it affects your smile too. Dr. Joseph T. Sumrall and Dr. Gran Sumrall, the dental gurus of Warner Robins, Georgia, are laying out why more adults are jumping on the cosmetic dentistry bandwagon as they age. Spoiler: It ain't about getting a movie-star grin but something much deeper....

Continue Reading
Lear Gears Up for Goldman Sachs Event Spotlight

Updated Category News Views 23

Lear Prepares for the Big Stage in London Autumn leaves and industry insights are falling in full swing as Lear Corporation gets its ducks in a row for the upcoming Goldman Sachs 18th Annual Industrials & Autos Week. Kicking off on December 3, 2026, this gathering in London isn't just another checkbox on their corporate calendar—it's a prime moment in the spotlight....

Continue Reading
Cheyenne Real Estate: Neighborhood Nuances and Choices

Updated Category News Views 128

Unearthing the Hidden Dynamics of Cheyenne's Real Estate You've got this picturesque vision in your head of Cheyenne, Wyoming—a sprawling cowboy town with its wild winds and wide-open spaces. But if you think all those neighborhoods are cut from the same cloth, you've got another thing coming. The real estate scene here is just as varied as the prairies stretching out...

Continue Reading
Gwen Stefani Kicks Off OCVIBE's New Concert Hall

Updated Category News Views 199

A Homecoming Steeped in Nostalgia Orange County’s about to do a serious throwback, folks! Gwen Stefani is set to headline the opening concert at OCVIBE's spanking new concert hall in Anaheim on March 17, 2027. Curious choice for their opener? Hardly. This gal's practically woven into the county’s tapestry—her roots run deep here, enough to make even the casual music...

Continue Reading

Top 5 Most Recently Viewed Articles

Formula Wellness Scores Top 50 Position from Allergan

Updated Category News Views 15

Pushing Boundaries in Aesthetic and Wellness Here's something you don't see every day: Formula Wellness just landed Top 50 status for 2026 from Allergan Aesthetics, the same folks who brought Botox to the world. It’s no small feat, and if you've been keeping an eye on sectors blending wellness with aesthetics, this might be the story to watch. Formula Wellness isn't...

Continue Reading
iTeos Therapeutics Showcases Inupadenant Trial Insights at ESMO

Updated Category News Views 98

Introduction to iTeos Therapeutics and ESMO Congress iTeos Therapeutics, Inc. (NASDAQ: ITOS), based in Watertown, Mass. and Gosselies, Belgium, is making strides in the field of biopharmaceuticals. Their mission focuses on pioneering a new wave of immuno-oncology therapies aimed at fighting cancer. The excitement around their innovative approaches is palpable, especially...

Continue Reading
Plastic vs. Metal Parts: The Manufacturing Showdown

Updated Category News Views 65

Understanding the Material Dilemma In manufacturing, a pivotal choice emerges early on: plastic or metal? It's a game-changer in product development, according to Ryan Eggleston from UTP Solutions. The stakes are high because picking the right material can define the success—or failure—of a product design. The Rise of Plastics Plastics have carved out a strong niche...

Continue Reading
Fast Debt Recovery Specialist Sets New Standards in Compliance

Updated Category News Views 105

Fast Debt Recovery Specialist Earns Newly Required License Fast Debt Recovery Specialist has marked a major milestone, becoming one of the first firms in Singapore to secure the government’s newly required debt collection license. It’s a clear signal: the agency intends to operate squarely within the law while holding fast to ethical, transparent recovery practices....

Continue Reading
Rivian's 2024 Performance: Impressive Production and Delivery Stats

Updated Category News Views 327

Rivian Announces Strong Production and Delivery Figures for 2024 Rivian Automotive, Inc. (NASDAQ: RIVN), a leading player in the electric vehicle market, has revealed its impressive production and delivery totals for 2024. The company successfully produced a remarkable 12,727 vehicles in the fourth quarter alone, rounding off a total annual production of 49,476 vehicles....

Continue Reading